Revelation Biosciences (NASDAQ:REVB) Trading Down 1.9% – Here’s What Happened

Revelation Biosciences, Inc. (NASDAQ:REVB) fell 1.9% during trading on Wednesday . The company traded as low as $1.02 and last traded at $1.03. Approximately 17,868 shares traded hands during mid-day trading, a decline of 62% from the average daily volume of 47,198 shares. The stock had previously closed at $1.05.

Wall Street Analyst Weigh In

Separately, Weiss Ratings lowered Revelation Biosciences from a “sell (e+)” rating to a “sell (e)” rating in a research report on Thursday, June 18th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has a consensus rating of “Sell”.

Revelation Biosciences Price Performance

The firm’s 50 day moving average price is $1.07 and its 200-day moving average price is $1.85. The stock has a market cap of $4.03 million, a P/E ratio of -0.03 and a beta of -0.09.

Revelation Biosciences (NASDAQ:REVB) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($2.71) earnings per share for the quarter, missing the consensus estimate of ($1.15) by ($1.56). On average, analysts expect that Revelation Biosciences, Inc. will post -4.99 earnings per share for the current year.

Institutional Trading of Revelation Biosciences

Institutional investors and hedge funds have recently modified their holdings of the business. Geode Capital Management LLC purchased a new position in shares of Revelation Biosciences in the fourth quarter worth $27,000. Armistice Capital LLC purchased a new stake in shares of Revelation Biosciences during the third quarter valued at $114,000. Finally, Sabby Management LLC boosted its position in shares of Revelation Biosciences by 214.7% during the third quarter. Sabby Management LLC now owns 207,051 shares of the company’s stock valued at $294,000 after buying an additional 141,262 shares during the last quarter. Institutional investors own 12.80% of the company’s stock.

Revelation Biosciences Company Profile

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.